Speakers:
- Alisa Serio, Executive Director of Microbiology and Nonclinical Development, Paratek Pharmaceuticals (USA)
- Victoria Savage, Chief Scientific Officer, INFEX Therapeutics Ltd (UK)
Moderator:
- Daniel Ritz, Senior Director – Senior Group Leader Biology Technologies / Lead Discovery, Idorsia Pharmaceuticals Ltd. (Switzerland)
This webinar focused on the particular challenges regarding progressing antibacterial drug discovery projects for small and medium-sized enterprises (SMEs) and their potential solutions.
Presentation 1: Progression criteria and go/no go decisions in antibacterial drug discovery – a perspective from Paratek Pharma (Alisa Serio)
- Overview of the drug discovery process through approval & commercialization
- Consideration of program origination and strategy within SMEs
- How non-dilutive funding can play a key role in SME programs
- Examples of go/no-go decisions
Presentation 2: Progressing an antibacterial drug discovery program – a perspective from INFEX Therapeutics (Victoria Savage)
- Introduction to the role of SMEs in antibacterial drug development
- Where SMEs fit in the development pipeline
- Challenges for SMEs
- Case studies for successful and unsuccessful programs
This live webinar including an interactive Q&A session was broadcast on 27 June 2024.
If you have questions or comments, please let us know: revive@gardp.org.